Skip to content
Innovation & R&D · DSIR-approved

India-first, global-first formulations.

Biodeal's DSIR-approved R&D centre turns molecules into regulated-market products — designing the formulation, the device and the dossier in-house, from first prototype to commercial launch.

DSIR
Govt-recognised R&D centre
25
R&D scientists & F&D resources
7
Active development projects
4
US-market projects in pipeline
Flagship · Nasal spray device science

The science behind a metered dose.

Intranasal delivery is a precision-engineering problem as much as a formulation one. We characterise plume geometry, particle-size distribution and spray pattern against validated specs — then match the pump architecture to the dose.

Biodeal Midazolam Nasal Spray 1.25% w/v — metered-dose intranasal device and cartonMidazolam Nasal Spray · 1.25% w/v · metered-dose
Plume geometry
25–55° validated
Spray plume angle measured and validated for consistent nasal deposition.
Particle size
Dv50 · 35 µm
Droplet-size distribution controlled to target the nasal mucosa, not the lungs.
Pump accuracy
100 µl · ±2%
Metered actuation delivers a precise, repeatable dose, shot after shot.
Spray pattern
Characterised
Spray-pattern and shot-weight testing through the device's in-use life.
Pump architecture
Snap-On360°SqueezeCrimp-On

From molecule to metered device.

Metered-dose, aqueous, saline, antihistamine, corticosteroid and nicotine BP formats — formulated, filled and sealed in-house under WHO-GMP, with pump selection and fill-volume specified at the R&D stage.

Full nasal spray CDMO
Fig. 06.2 · Dry powder inhaler
Device formatCapsule-based DPI
Capsule capabilityDPI capsule fill
DeliveryBreath-actuated
Inhalation devices

Dry powder inhalers, device and capsule.

Beyond nasal, Biodeal extends its respiratory-delivery depth into dry powder inhalation — both the DPI device and the DPI capsule manufacturing that feeds it — for fine-particle pulmonary delivery without propellants.

01

DPI device

Breath-actuated capsule inhalers engineered for consistent fine-particle dose to the lung.

02

DPI capsule

In-house capsule filling and capability — the metered powder payload the device pierces and delivers.

R&D pipeline

A working pipeline, not a brochure promise.

Biodeal's DSIR-approved development centre runs a live portfolio — staffed by formulation & development resources and qualified scientists, weighted toward regulated and first-in-market filings.

R&D team
25 people

A combined bench of 14 formulation & development resources and 11 qualified scientists working concept-to-commercial, in-house.

14 F&D+11 Scientists
Development centre
DSIR approved

A government-recognised R&D centre — formulation design, ICH stability studies and CTD/ACTD dossier preparation, concept to commercial.

Formulation+Dossier
Active projects
7

Live development projects in flight across dosage forms and markets.

US-market
4

Projects targeting US-market registration and the most demanding regulators.

India-first vs global-first.

Of the seven active projects, the split is weighted toward products developed for the world market before — or alongside — India.

3–4
India-first formulations
3
Global-first formulations
India-first — launched in India ahead of export Global-first — developed for regulated export markets
R&D services

From a validated molecule to a registered product.

A single, accountable development partner — covering formulation design, the studies regulators demand, and the dossier that gets your product to market.

01Formulation developmentNew formulation design across pharma, nutraceutical, nasal spray, injectable and herbal categories — from prototype to robust commercial formula.Pharma · Nutra · Nasal · Injectable
02ICH stability studiesICH-guideline accelerated and long-term studies, run across climatic zones I–IV to support filings in any destination market.Climatic zones I–IV
03Analytical method dev & validationHPLC, GC, dissolution, content-uniformity and microbiological methods — developed and validated for every product.HPLC · GC · Dissolution
04Bioequivalence supportComparative dissolution studies and BE-study support for generic pharmaceutical registration.Comparative dissolution · BE
05Regulatory dossier (CTD / ACTD)CTD and ACTD dossier preparation and product-registration support for Indian and international markets.CTD / ACTD
06Technology transfer & scale-upSeamless transfer from R&D to pilot batch to full commercial manufacturing — under one quality system.R&D → Pilot → Commercial
Quality & testing infrastructure

Methods that hold up to any pharmacopoeia.

A modern QC backbone underwrites every formulation — validated analytical methods, multi-pharmacopoeia compliance and stability data generated to the standard the next market will ask for.

Stability

ICH stability chambers

Accelerated and long-term studies across the four ICH climatic zones, generating the shelf-life data regulators require.

Zone IZone IIZone IIIZone IVa/IVb
Analytics

Validated QC methods

HPLC, GC and dissolution instrumentation with validated methods and in-process plus finished-product release testing.

HPLCGCDissolutionContent uniformity
Compliance

Multi-pharmacopoeia

Testing to IP, BP, USP and other monograph standards — so a single development effort can clear multiple markets.

IPBPUSPCTD / ACTD
Enquire

Tell us what you need to make.

A focused brief gets you a routed answer from the right team within one working day.